简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Video
Research
HOME
·
RUIHE DATA
RUIHE DATA (03680.HK): Subsidiary Submits Subscription Application for Up to HKD 60,000,000 of Ligent Technologies International Offering Shares, Extending into Upstream AI Computing Optical Interconnect
Tags:
NewTimeSpace
RUIHE DATA
03680.HK
AI Computing
Optical Modules
2026-09-15
RUIHE DATA (03680.HK): H1 Profit Expected to Rise 27%-39% Despite Revenue Falling 17%-21%
Tags:
RUIHE DATA
03680.HK
positive profit alert
2026-08-13
RUIHE DATA (03680.HK): Establishes RMB 100 Million Venture Capital Fund with Indirect 11.9% Stake, Targeting Emerging Pillar and Future Industries
Tags:
RUIHE DATA
03680.HK
Partnership Agreement
2026-08-09
RUIHE DATA (03680.HK) plans to issue up to 44.96 million shares by placement, with estimated net proceeds of HKD 90.76 million
Tags:
RUIHE DATA
03680.HK
NewTimeSpace
2026-07-31
Featured News
Finance
CHINA HK POWER (00931.HK): To issue 50 million new shares at HKD 0.290 each, net proceeds about HKD 14.3 million
Finance
CAPITAL REALM (00204.HK): Signs letter of intent for strategic cooperation on AI computing-power intelligent robotics
Finance
TIANYU SEMI (02658.HK): Approves H share repurchase plan of up to 5,899,042 shares
Finance
ONEROBOTICS (06600.HK): Scheme trustee purchases further 101,200 H shares, cumulative holdings reach 653,200
Finance
YAN PALACE (01497.HK): Enters product sales and purchase framework agreement with Shenzhen Yan Palace, 2028 annual cap at RMB 55 million
Finance
ORANGE SKY G H (01132.HK): Appoints Du Yan as Independent Non-Executive Director and Chairman of the Remuneration Committee, Replacing Huang Siying
Finance
VALUES CULTURAL (01740.HK): Appoints Miao Jian as Executive Director and Co-Chief Executive Officer, with Cai Xiaoxin Serving as Co-CEO
Finance
BOAN BIOTECH (06955.HK): Masked PD-1/IL-2 Prodrug BA1203 Approved for Clinical Trial in China for Multiple Solid Tumours
Finance
WEIHAI BANK (09677.HK): Completes Issue of RMB 500 Million 2026 Green Financial Bonds (First Tranche) at 1.65% Coupon
Finance
HENGRUI PHARMA (01276.HK): Marketing Application for Class 1 Innovative Drug SHR-2004 Injection Accepted by NMPA for VTE Prevention After Knee Replacement Surgery
Scan QR Code
Download App